Q2 2024 Tarsus Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Tarsus Pharmaceuticals Inc (TARS) reported a significant 65% increase in sales from Q1 to Q2 2024, generating over $40 million in sales.
- The company has achieved exceptional high-quality payer coverage, with contracts secured with major commercial and Medicare payers.
- Approximately 11,000 eye care providers (ECPs) are prescribing XDEMVY, with more than 60% prescribing it to multiple patients.
- Tarsus Pharmaceuticals Inc (TARS) is expanding its sales force and planning a consumer television campaign to further accelerate growth.
- The company is advancing a robust pipeline with plans to bring three programs to the FDA by the end of the year, focusing on meibomian gland disease, Lyme disease prevention, and rosacea.
- The gross to net discount remains relatively high at approximately 44%, which could impact profitability.
- There is an anticipated increase in the gross to net discount due to the Medicare donut hole, potentially affecting financial performance in the second half of the year.
- Operating expenses increased by approximately $9.5 million in Q2 2024, driven by sales and marketing costs and the expanded sales force.
- The company expects a modest growth rate of approximately 10% in bottles dispensed in Q3, partly due to the summer slowdown in ECP offices.
- There is a potential challenge in maintaining momentum as the company expands its sales force, which may temporarily disrupt operations.
Good afternoon, and welcome to the Tarsus second quarter 2024 financial results conference call. As a reminder, this call is being recorded. At this time, I would like to turn the call over to David Nakasone, Head of Investor Relations, to lead off the call. David, you may begin.
Thank you. Before we begin, I encourage everyone to go to the Investors section of the Tarsus website to the earnings release and related materials we will be discussing today. Joining me on the call this afternoon are Bobby Azamian, our Chief Executive Officer and Chairman; Aziz Mottiwala, our Chief Commercial Officer; Jeff Farrow, our Chief Financial Officer and Chief Strategy Officer, and joining us for the question-and-answer session, Sesh Neervannan, our Chief Operating Officer.
I'd like to draw your attention to slide 3, which contains our forward-looking statements. During this call, we will be making forward-looking statements that are based on our current expectations and beliefs. These statements
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
